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Background: Treatment options for patients with nonbulky stage IA–IIA Hodgkin lymphoma include combined modality
therapy (CMT) using doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus involved-ﬁeld radiation therapy
(IFRT), and chemotherapy with ABVD alone. There are no mature randomized data comparing ABVD with CMT using
modern radiation techniques.
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Patients and methods: Using German Hodgkin Study Group HD10/HD11 and NCIC Clinical Trials Group HD.6
databases, we identiﬁed 588 patients who met mutually inclusive eligibility criteria from the preferred arms of HD10 or 11
(n = 406) and HD.6 (n = 182). We evaluated time to progression (TTP), progression-free (PFS) and overall survival,
including in three predeﬁned exploratory subset analyses.
Results:With median follow-up of 91 (HD10/11) and 134 (HD.6) months, respective 8-year outcomes were for TTP, 93%
versus 87% [hazard ratio (HR) 0.44, 95% conﬁdence interval (CI) 0.24–0.78]; for PFS, 89% versus 86% (HR 0.71, 95% CI
0.42–1.18) and for overall survival, 95% versus 95% (HR 1.09, 95% CI 0.49–2.40). In the exploratory subset analysis
including HD10 eligible patients who achieved complete response (CR) or unconﬁrmed complete response (CRu) after two
cycles of ABVD, 8-year PFS was 87% (HD10) versus 95% (HD.6) (HR 2.8; 95% CI 0.64–12.5) and overall survival 96%
versus 100%. In contrast, among those without CR/CRu after two cycles of ABVD, 8-year PFS was 88% versus 74% (HR
0.35; 95% CI 0.16–0.79) and overall survival 95% versus 91%, respectively (HR 0.42; 95% CI 0.12–1.44).
Conclusions: In patients with nonbulky stage IA–IIA Hodgkin lymphoma, CMT provides better disease control than ABVD
alone, especially among those not achieving complete response after two cycles of ABVD. Within the follow-up duration
evaluated, overall survivals were similar. Longer follow-up is required to understand the implications of radiation and
chemotherapy-related late effects.
Clinical trials: The trials included in this analysis were registered at ClinicalTrials.gov: HD10 - NCT00265018,
HD11 - NCT00264953, HD.6 - NCT00002561.
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introduction
There is considerable debate about optimum management of
patients with nonbulky stage IA and IIA Hodgkin lymphoma
[1]. One practice guideline recommends a single option of
combined modality therapy (CMT) consisting of two to four
cycles of doxorubicin, bleomycin, vinblastine and dacarbazine
(ABVD) plus involved-ﬁeld radiation therapy (IFRT) [2];
another includes ABVD alone as an acceptable alternative [3].
Three randomized, controlled trials (RCTs) contribute to these
recommendations [4–6]. The German Hodgkin Study Group
(GHSG) evaluated CMT in two RCTs that included patients
with favorable (HD10) [4] and unfavorable (HD11) [5] limited-
stage disease. Based on disease control at median follow-up of
91 months, results of HD10 demonstrated that two cycles of
ABVD plus 20 Gy IFRT was noninferior to CMT that included
four cycles of ABVD and 30 Gy IFRT. In HD11, four cycles of
ABVD and 30 Gy IFRT remained standard treatment, when
neither noninferiority of four cycles of ABVD and 20 Gy IFRT,
nor superiority of CMT that included standard doses of
bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine and prednisone (BEACOPP) followed
by 30 Gy IFRT were observed. The strategy of ABVD alone was
tested in the NCIC Clinical Trials Group (NCIC CTG)–Eastern
Cooperative Oncology Group (ECOG) HD.6 trial [6, 7]; with a
median follow-up of 11.3 years, those allocated to four to six
cycles of ABVD alone experienced superior overall survival in
comparison with patients receiving treatment that included
subtotal nodal radiation therapy (STNRT) [6]. This was
attributed to observing fewer deaths from causes unrelated to
progressive Hodgkin lymphoma. Because STNRT represents
outdated therapy, there is a desire to understand how results of
the HD.6 ABVD-alone cohort might compare with those
achieved using modern CMT. Comparing outcomes of HD10/
11 and HD.6 is complicated by differences in eligibility, end
points and follow-up durations. We conducted this exploratory
study describing outcomes of mutually inclusive patients from
these three RCTs to help inform the current debate and to
generate hypotheses that assist formulating future research
directions.
methods
This NCIC CTG-GHSG collaborative analysis utilized anonymized
individual patient data. All patients provided written informed consent at
trial entry. Approvals from research ethics boards (REBs) were obtained
from all treatment centers. Both Groups obtained updated REB approvals
for this project.
Potentially eligible patients had previously untreated nonbulky stage IA–
IIA Hodgkin lymphoma and were randomized to receive two cycles of ABVD
and 20 Gy IFRT (HD10), four cycles of ABVD and 30 Gy IFRT (HD11) or
four to six cycles of ABVD alone (HD.6). Patients were required to be eligible
for HD.6 and either HD10 or HD11, as determined by baseline characteristics
at the time of original study entry. Eligible patients fromHD.6 with extranodal
involvement, an erythrocyte sedimentation rate (ESR) of 50 or greater, or
three or more nodal areas of Hodgkin lymphoma were assigned to the HD11
subset, others were assigned to HD10. Computer programming was utilized to
map anatomic distribution of disease to nodal areas (GHSG) and disease sites
(NCIC CTG). Response after two cycles of ABVD was collated for HD10 and
HD.6 patients (response was not assessed after two cycles in HD11). Response
assessments were carried out using CT scanning; no assessments included
positron emission tomographic (PET) scanning.
Outcomes were deﬁned using Revised Response Criteria for Malignant
Lymphoma [8]. Patients meeting mutually inclusive eligibility criteria were
grouped into two cohorts: those randomized to CMT on HD10/11 and to
ABVD only on HD.6. As our analysis would be underpowered for deﬁnitive
conclusions, no prespeciﬁed hypothesis was deﬁned, no P-values are
reported and all comparisons are considered exploratory. Cox models
stratiﬁed by propensity score were used to obtain hazard ratios (HR) and
95% conﬁdence intervals (CI) for time to progression (TTP), progression-
free survival (PFS) and overall survival, and are expressed as outcomes of
HD10 and/or HD11 relative to HD.6. Prespeciﬁed exploratory subset
analyses were eligibility for HD10 versus HD11, favorable versus unfavorable
risk according to HD.6 criteria and complete response or unconﬁrmed
complete response (CR/CRu) versus no CR/CRu after two cycles of ABVD
among those eligible for both HD10 and HD.6. Complete methodological
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details are provided in the supplementary Appendix, available at Annals of
Oncology online.
results
Of 655 eligible patients allocated to the selected arms of HD10
and HD11, 406 (62%) were eligible for HD.6; 254 of 299 (85%)
from HD10 and 152 of 356 (43%) from HD11. The most
common reasons for ineligibility were B symptoms and large
mediastinal mass. Of 196 eligible HD.6 patients randomized to
ABVD alone, 182 (93%) are included; 110 eligible for HD10 and
71 eligible for HD11. One patient was unassigned as the ESR
was unavailable. Stage IA lymphocyte predominant disease and
reduced creatinine clearance accounted for ineligibility for
HD10/11 (supplementary Appendix, available at Annals of
Oncology online). Baseline characteristics of mutually eligible
patients are provided in the on-line appendix (supplementary
Appendix, available at Annals of Oncology online). Median age
was 35 years and balanced between cohorts. A greater
proportion of HD.6 patients had nodular sclerosing histology
and stage IA disease. Median follow-up durations were 92
months for HD10, 91 months for HD11 and 134 months for
HD.6.
The TTP was superior for GHSG patients with 8-year
estimates of 93% versus 87% (HR 0.44; 95% CI 0.24–0.78). All
TTP events in both cohorts were due to progressive disease. The
8-year PFS was 89% for GHSG HD10/11 patients allocated to
two to four cycles of ABVD followed by IFRT and 86% for
NCIC CTG HD.6 patients allocated to four to six cycles of
ABVD alone (HR 0.71; 95% CI 0.42–1.18). The nature of the
PFS events is shown in Table 1. The 8-year overall
survival estimates were 95% in both cohorts (HR 1.09; 95% CI
0.49–2.40).
Among 364 patients mutually eligible for HD10, respective
8-year GHSG and NCIC CTG outcomes for TTP were 93% and
85% (HR 0.43, 95% CI 0.22–0.85), for PFS were 87% and 82%
(HR 0.58; 95% CI 0.32–1.05) and for overall survival were 96%
and 94% (HR 0.65, 95% CI 0.25–1.72) (supplementary
Appendix, available at Annals of Oncology online). Discrepant
outcomes were suggested according to CR/CRu status after two
cycles of ABVD. Among the 202 patients achieving a CR/CRu
after two treatment cycles, the 8-year PFS of GHSG patients was
87% and among NCIC CTG patients was 95% (HR 2.83; 95% CI
0.64–12.49). The 8-year overall survivals were 96% and 100%,
respectively. In contrast, among the 162 not achieving a CR/
CRu status, continuation with IFRT instead of ABVD improved
8-year PFS (88% versus 74%; HR 0.35, 95% CI 0.16–0.79),
respective 8-year overall survivals were 95% and 91% (HR 0.42;
95% CI 0.12–1.44). For the 223 patients mutually eligible for
HD11, the 8-year TTPs were 94% (GHSG) and 91% (NCIC
CTG) (HR 0.60, 95% CI 0.21–1.73), the 8-year PFS for both
cohorts was 91% (HR 1.15; 95% CI 0.45–2.97), and overall
survivals were 95% and 97% (HR 2.03; 95% CI 0.53–7.79).
Among 162 patients deﬁned as having favorable-risk disease
according to HD.6 protocol criteria, the respective 8-year TTPs
of GHSG and NCIC CTG cohorts were 92% and 91% (HR 0.72;
95% CI 0.25–2.12), PFSs were 92% and 91% (HR 0.77; 95% CI
0.26–2.3) and overall survivals were 99% and 98% (HR 0.51;
95% CI 0.03–8.07). For those meeting HD.6 unfavorable-risk
criteria, respective 8-year TTPs were 94% and 86% (HR 0.40;
95% CI 0.20–0.80), PFSs were 87% and 84% (HR 0.71; 95% CI
0.40–1.28) and 8-year overall survivals were 94% versus 94%
(HR 1.10, 95% CI 0.48–2.54).
Among 406 GHSG patients with median follow-up of 91
months, there were 19 deaths with 7 attributed to Hodgkin
lymphoma or immediate treatment toxicity and 12 to other
causes. Among 182 NCIC CTG patients with median follow-up
of 134 months, there have been 10 deaths; 5 were attributed to
Hodgkin lymphoma or immediate treatment toxicity and 5 to
other causes. Additional tables and ﬁgures are presented in the
supplementary Appendix, available at Annals of Oncology online.
discussion
Long-term outcomes of patients with nonbulky stage IA–IIA
Hodgkin lymphoma require treatment strategies that balance
establishing complete disease control while reducing the risk of
late treatment effects. Clinical trials of the past two decades have
demonstrated that CMT including IFRT is as effective and has
fewer late treatment effects [9] when compared with CMT that
includes STNRT [10]. Thus, CMT that includes IFRT currently
represents a standard of care, with a recognized limitation that
comparisons of large patient numbers followed after initial
treatment into the second decade and beyond have not yet been
reported. While the incidence and severity of late treatment
effects including secondary malignancies and cardiovascular
disease attributable to IFRT is less than with more extensive
radiation therapy, the magnitude of this reduction and the
importance of remaining risks are uncertain. Recent
innovations in radiation therapy include involved involved-site
Table 1. Outcome measures and end point events of 588 patients with
nonbulky stage I–IIA Hodgkin lymphoma





8-year TTPa 93% 87% 0.44 0.24, 0.78
Total events 25 23
PD events 25 23
Survival events 0 0
8-year PFSb 89% 86% 0.71 0.42, 1.18
Total events 38 27
PD eventsc 25 23
Survival events 13 4
8-year OS 95% 95% 1.09 0.49, 2.40
Survival events 19 10
aTime to progression (TTP) was measured from date of randomization to
the ﬁrst of date of PD or death attributed to progressive Hodgkin
lymphoma.
bProgression-free survival (PFS) was measured from date of randomization
to the ﬁrst of date of progressive disease (PD event) or death (survival event)
from any cause.
cFor six patients in each cohort, PD was later followed by death; only the PD
event is captured in PFS. These deaths were not necessarily attributed to
Hodgkin lymphoma.
GHSG, German Hodgkin Study Group; NCIC CTG, NCIC Clinical Trials
Group; HR, hazard ratio; CI, conﬁdence intervals; OS, overall survival.
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radiation therapy (ISRT) which is considered an alternative to
IFRT according to the 2013 National Comprehensive Cancer
Network guidelines [11], involved-node radiation therapy [12]
(INRT), which has been adopted by some institutions and by
the European Organisation for Research and Treatment of
Cancer in its H10 trial [13], conformal radiation [14] and
proton therapy [15]. Each of these strategies represents a
potential advancement in balancing disease control with the
risk of late treatment effects, but to date, there are no
publications of RCTs comparing these strategies or of follow-up
into the period during which late-effects become evident.
The NCIC CTG-ECOG HD.6 trial demonstrated that four to
six cycles of ABVD alone is associated with long-term disease
control in 87% of patients. This magnitude of disease control
was 5% worse than observed in patients treated with a strategy
that included STNRT and 8% worse in a subset analysis that
included patients assigned to CMT that included STNRT.
However, overall survival was superior because there were fewer
deaths from other causes. While recognizing that these relative
outcomes cannot be directly generalized to CMT that includes
IFRT, the results have led to treatment with ABVD alone also
being considered a standard care alternative. Limitations
associated with ABVD alone include the increased risk of
disease recurrence, late-effect risks associated with subsequent
lines of therapy and the potential for anthracycline-induced
cardiotoxicity [16].
This analysis informs, but does not resolve, ongoing debates.
Our data are consistent with previous observations that long-term
disease control is superior with CMT. This is best demonstrated
by TTP, an end point that in our combined populations was
always due to progressive disease. Our analysis supports previous
data that suggest CMT is associated with 8-year TTP superiority
of the magnitude of 6% (93% versus 87%). Our data also suggest
that overall survival within the ﬁrst decade of follow-up is unlikely
to differ between these two treatment options as 8-year estimates
were of 95% for both cohorts.
Observations from our predeﬁned subset analysis show
striking differences in disease-control outcomes of patients
eligible for HD10 according to CR/CRu status assessed by CT
scan and physical examination after two cycles of ABVD,
leading us to conclude that patients not achieving a CR/CRu at
this time point should receive CMT; the 8-year TTP with ABVD
alone was inferior to CMT (92% versus 78%). In contrast, the
excellent 8-year outcomes of patients assigned to ABVD alone
who achieved a CR/CRu status after two cycles of ABVD (TTP
of 95%; overall survival of 100%) support treatment with ABVD
alone. This strategy of response-adapted therapy now includes
the ability to incorporate PET scanning into the decision-
making process. Preliminary results of two RCTs testing interim
PET scanning are now available. Radford [17] has reported
outcomes of 420 patients with a negative PET scan after three
cycles of ABVD: among those receiving no further therapy, the
3-year PFS was 90.7% in comparison with 93.8% among those
randomized to receive IFRT. The 3-year overall survivals were
99.5% among those allocated to no further therapy and 97%
among those allocated to IFRT. The authors concluded that
IFRT was unnecessary for patients with a negative PET scan
after three cycles of ABVD. In contrast, Andre has reported
results of an RCT involving 382 favorable risk patients
comparing CMT that includes three cycles of ABVD and INRT
with a PET-directed, response-adapted approach; after two
cycles of ABVD those with a negative PET scan receive two
further cycles of ABVD and no radiation treatment. The 1-year
PFS outcomes in the PET negative cohort were 94.9% with
ABVD alone versus 100% with additional INRT, which led to a
recommendation by the data safety monitoring committee of
the trial to halt accrual to this arm. It is not expected that either
of these trials will be able to report overall survival outcomes of
the duration we report in this analysis for at least 5 years.
Additional data will come from the GHSG HD16 and HD17
trials, which also compare nonrisk-adaptive CMT approaches
with a PET-directed, response-adapted strategy.
Our study has important limitations. Although data were
prospectively collected within the conduct of RCTs, our
analyses are retrospective and biases due to imbalances of
baseline patient characteristics, co-interventions, end point
measurement and frequencies and nature of follow-up likely
exist. Our analyses have limited statistical power. The median
follow-up durations of the two cohorts differed by 42 months,
with even the 134-month median follow-up of the HD.6 cohort
being insufﬁcient for detailed understandings of late-effect risks.
Our analyses, while exploratory, help generate hypotheses for
future research. The populations considered were assembled
according to two risk-stratiﬁcation schema, which include
disease and patient-related factors. The HD10 and HD11
cohorts differ by disease-related factors only. As HD.6 eligibility
criteria excluded those with bulky disease and B symptoms, the
remaining eligibility differences between HD10 and HD11 were
the presence of extranodal disease, number of nodal areas of
disease and ESR elevation. Recognizing that GHSG patients
entered on to HD11 received more cycles of chemotherapy than
those entered on to HD10, our data do not show obvious
prognostic differences between either the GHSG or NCIC CTG-
ECOG populations according to their eligibility for HD10 and
HD11. Overall survivals were similar among those eligible for
HD10 when compared with HD11 in both the GHSG and
NCIC CTG cohorts and among those eligible for HD11, TTP
did not appear to differ between the GHSG and NCIC CTG-
ECOG cohorts. In fact, among the NCIC CTG cohort, TTP
appeared to be worse in those eligible for HD10 (supplementary
Appendix, available at Annals of Oncology online), a ﬁndings
that may be due to imbalances of other factors between these
risk groups such as age, or other baseline characteristics. Still,
exploration of this ﬁnding might consider whether a select
proportion of patients with fewer nodal sites may harbor disease
that is more biologically aggressive. In contrast, the risk-
stratiﬁcation schema used in HD.6 included a patient factor,
age, in addition to disease-related factors. Using this schema,
inferior survival of unfavorable-risk patients is suggested in both
the GHSG and NCIC CTG cohorts. Among the combined
favorable cohorts there were two deaths, both attributed to
progressive Hodgkin lymphoma. In contrast among the
combined unfavorable cohorts there were 25 deaths with 16
attributed to causes other than progressive Hodgkin lymphoma.
These ﬁndings are consistent with previous observations that
older age is associated with poorer survival [18] through a
relation with an increased risk of deaths from causes other than
progressive Hodgkin lymphoma and invite evaluation of
original articles Annals of Oncology
 | Hay et al. Volume 24 | No. 12 | December 2013
whether risks of late treatment effects are observed after a briefer
period of follow-up in older patients [1]. Better understandings
of the factors associated with the hypotheses generated by these
data might provide insights into whether either of the two
treatment strategies tested have a potential for differential
beneﬁt for a speciﬁc population.
Our analyses demonstrate potential limitations of end points
used in clinical trials evaluating patients with
lymphoproliferative disorders. Patients with stage IA-IIA
nonbulky Hodgkin lymphoma typically do not have systemic
illness and, compared with patients who have metastatic
carcinoma or fulminant lymphoma, are highly unlikely to die
directly due to lymphoma unless there is prior progressive
disease. In our analysis, all 48 TTP events were due to
progressive disease. In contrast, PFS has features of a composite
end point, as progressive disease and death from any cause are
included, with deaths attributed to treatment-related late-effects
or unrelated causes. Reporting of outcomes associated with the
individual end points included within a composite has been
recommended, as each may be associated with distinct
weighting when considered from different perspectives [19].
While our analysis is limited by its nonrandomized design
associated with potential for bias and has limited statistical
power, the data suggest that differences in the proportions of
individual end points that constitute the composite can occur.
In conclusion, our exploratory analyses align with other data
showing that for patients with nonbulky stage IA-IIA Hodgkin
lymphoma, CMT including IFRT improves long-term disease
control compared with ABVD alone. This appears to be so
especially among patients with fewer pretreatment anatomical
areas of Hodgkin lymphoma who do not enter a CR/CRu status
after two cycles of ABVD. To date, no differences in overall
survival are detected. Longer follow-up of trials evaluating
treatment options for these patients is needed to properly assess
that end point.
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